Differentiated Embryo-Chondrocyte Expressed Gene1 and Parkinson’s Disease: New Insights and Therapeutic Perspectives-Reference-Cited by-同舟云学术

Differentiated Embryo-Chondrocyte Expressed Gene1 and Parkinson’s Disease: New Insights and Therapeutic Perspectives

Published:2023-11 Issue:11 Volume:21 Page:2251-2265
ISSN:1570-159X
Container-title:Current Neuropharmacology
language:en
Short-container-title:CN

Author:

Wang Chun-Yan¹,Qiu Zheng-Jie¹,Zhang Ping²,Tang Xiao-Qing³

Affiliation:

1. Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, China

2. The Affiliated Nanhua Hospital, Department of Neurology, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China

3. Hengyang Key Laboratory of Neurodegeneration and Cognitive Impairment, Institute of Neuroscience, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, China

Abstract

Abstract: Differentiated embryo-chondrocyte expressed gene1 (DEC1), an important transcription factor with a basic helix-loop-helix domain, is ubiquitously expressed in both human embryonic and adult tissues. DEC1 is involved in neural differentiation and neural maturation in the central nervous system (CNS). Recent studies suggest that DEC1 protects against Parkinson's disease (PD) by regulating apoptosis, oxidative stress, lipid metabolism, immune system, and glucose metabolism disorders. In this review, we summarize the recent progress on the role of DEC1 in the pathogenesis of PD and provide new insights into the prevention and treatment of PD and neurodegenerative diseases.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Hunan Province

Hunan Provincial Innovation Foundation for Postgraduate

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology,General Medicine

Reference153 articles.

1. Dorsey E.R.; Elbaz A.; Nichols E.; Abbasi N.; Abd-Allah F.; Abdelalim A.; Adsuar J.C.; Ansha M.G.; Brayne C.; Choi JY.J.; Collado-Mateo D.; Dahodwala N.; Do H.P.; Edessa D.; Endres M.; Fereshtehnejad S-M.; Foreman K.J.; Gankpe F.G.; Gupta R.; Hamidi S.; Hankey G.J.; Hay S.I.; Hegazy M.I.; Hibstu D.T.; Kasaeian A.; Khader Y.; Khalil I.; Khang Y-H.; Kim Y.J.; Kokubo Y.; Logroscino G.; Massano J.; Mohamed Ibrahim N.; Mohammed M.A.; Mohammadi A.; Moradi-Lakeh M.; Naghavi M.; Nguyen B.T.; Nirayo Y.L.; Ogbo F.A.; Owolabi M.O.; Pereira D.M.; Postma M.J.; Qorbani M.; Rahman M.A.; Roba K.T.; Safari H.; Safiri S.; Satpathy M.; Sawhney M.; Shafieesabet A.; Shiferaw M.S.; Smith M.; Szoeke C.E.I.; Tabarés-Seisdedos R.; Truong N.T.; Ukwaja K.N.; Venketasubramanian N.; Villafaina S.; weldegwergs K.; Westerman R.; Wijeratne T.; Winkler A.S.; Xuan B.T.; Yonemoto N.; Feigin V.L.; Vos T.; Murray C.J.L.; Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018,17(11),939-953

2. Ascherio A.; Schwarzschild M.A.; The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol 2016,15(12),1257-1272

3. Armstrong M.J.; Okun M.S.; Diagnosis and Treatment of Parkinson Disease. JAMA 2020,323(6),548-560

4. Atchley W.R.; Fitch W.M.; A natural classification of the basic helix–loop–helix class of transcription factors. Proc Natl Acad Sci USA 1997,94(10),5172-5176

5. Ledent V.; Vervoort M.; The basic helix-loop-helix protein family: comparative genomics and phylogenetic analysis. Genome Res 2001,11(5),754-770